世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

北米の高リン血症治療薬市場予測 2019-2027年

NORTH AMERICA HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2018年11月US$1,250
シングルユーザライセンス(印刷不可PDF)
80

サマリー

この調査レポートは北米の高リン血症治療薬市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS
The North America hyperphosphatemia drug market is expected to grow at a CAGR of 15.19% over the forecast period. The region is expected to hold the largest share in the market with an anticipated increase in the revenue from $xx million in 2018 to $xx million by 2027. Diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. Increasing prevalence of these chronic diseases along with unattended medical needs are driving the hyperphosphatemia drug market in this region.
MARKET INSIGHTS
The changing dietary patterns along with the increasing cases of osteoporosis diseases in countries like the United States and Canada are providing the hyperphosphatemia drug market with plenty of growth opportunities. The market is mainly categorized by the different types of drug binders such as iron-based phosphate binders, magnesium-based phosphate binders, aluminium-based phosphate binders, calcium-based phosphate binders and others. The aluminium-based phosphate binders generated revenue of $203 million in 2016 and are widely used with magnesium-based phosphate binders for treating patients on dialysis. However, it is the calcium-based phosphate binders that held the largest market share of xx% in 2018 and are expected to continue their dominance throughout the forecasted period. Despite such phenomenal growth, the market is facing some tough challenges due to the various limitations imposed by the Food and Drug Administration (FDA) and the rising side effects observed due to the use of some of the hyperphosphatemia drugs.

COMPETITIVE INSIGHTS

Some of the eminent companies in the hyperphosphatemia drug market include Royal Dsm, Amag, Sun Pharma, and Keryx. Other top players in the market are Zeria Pharmaceutical, Johnson and Johnson, Bruno Pharmaceutical Spa, Cipla, Ultragenyx, Fresenius Medical Care, Roche Diagnostics Corporation, R.H. Moore Drug Co., Sanofi, Fermenta Biotech Ltd, Vifor Pharma, Shire and Pfizer Inc.



 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る